{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 39,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Slide 26 of a clinical presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/26",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.848,
        "x": 0.076,
        "y": 0.55
      },
      "kind": "list",
      "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population, with responses observed in patients with and without ROS1 G2032R resistance, prior progression, and brain metastases.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49eca47c-7571-4a60-ad3c-11467ba4f83c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.848,
        "x": 0.076,
        "y": 0.83
      },
      "kind": "list",
      "text": "Phase 1 ongoing to further understand the safety profile, PK, and preliminary efficacy, and determine the RP2D",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91180c9d-2b1d-4148-aa15-41405c655535",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.848,
        "x": 0.076,
        "y": 0.275
      },
      "kind": "list",
      "text": "In the ongoing ARROS-1 Phase 1 dose-escalation, a wide dose range resulted in exposures exceeding predicted efficacy thresholds without indication of off-target toxicity. NVL-520 has been well tolerated with no DLTs. No dose reductions or discontinuations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2fd0e3e-ec02-4884-bc97-ee4a4434aae6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.076,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose. Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6123819-fd06-4d18-9876-488d3e84cc43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.848,
        "x": 0.076,
        "y": 0.145
      },
      "kind": "title",
      "text": "NVL-520 is a brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c6becd6-36de-4393-bedd-ddab0172c310",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.464,
        "x": 0.076,
        "y": 0.105
      },
      "kind": "title",
      "text": "CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30543607-35b7-46af-a288-82138750f521",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}